Study Evaluating Prevenar in High-Risk Children

Wyeth

Status: Completed

Conditions: Pneumococcal Disease

Study type: Observational

Funder types: Industry

Identifiers

NCT00234338

101850

Details and patient eligibility

About

The purpose of this study is to estimate the local and systemic tolerability of Prevenar in children ages 2 to 5 years old in usual care settings.

Enrollment: 5,000 estimated patients

Sex: All

Ages: 2 to 5 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• High-risk children ages 2 to 5 years old

Exclusion criteria

• Prior administration of Prevenar
• Prior and/or concurrent administration of 23 vPs vaccine